CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
losartan +1 moredrug
Likely dose
losartan 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01150461
NCT01150461Phase 2Completed
CompareCT.gov

Effect of Losartan in Patients With Nonobstructive Hypertrophic Cardiomyopathy

Massachusetts General Hospital·interventional·Posted Jun 25, 2010·Updated Sep 5, 2013

In Brief

A Phase 2 clinical trial evaluating losartan and placebo for Hypertrophic Cardiomyopathy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether taking losartan helps people with hypertrophic nonobstructive cardiomyopathy feel better by decreasing the amount of heart muscle thickening and/or the amount of heart muscle scarring.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertrophic Cardiomyopathy
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 25, 2010
Enrollment StartFeb 1, 2007
Primary CompletionJul 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.0 years ago

Interventions

losartandrug

Losartan 50 mg b.i.d

placebodrug

Placebo b.i.d.